Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

ets

(1),(4) 27,408 30,782 33,897 37,670 41,775 33,566 37,980 40,828

-------------------------------------------------------------------------

Total

cash

(2),(4) 21,963 25,214 28,191 31,533 35,681 27,614 31,495 34,501

-------------------------------------------------------------------------

Total

long-term

debt(5) - - - - - 150 150 150

-------------------------------------------------------------------------

Cash

dividends

declared(6) Nil Nil Nil Nil Nil Nil Nil Nil

-------------------------------------------------------------------------

(1) Subsequent to the acquisition of Oncolytics Biotech Inc. by SYNSORB

in April 1999, we applied push down accounting. See note 2 to the

audited financial statements for 2007.

(2) Included in total cash are cash and cash equivalents plus short-term

investments.

(3) Included in net loss and loss per common share between March 2008 and

April 2006 are quarterly stock based compensation expenses of

$19,593, $396,278, $38,909, $82,573, $21,396, $109,670, $34,671, and

$222,376, respectively.

(4) We issued 4,600,000 units for net cash proceeds of $12,063,394 during

2007 with each unit consisting of one common share and one half of

one common share purchase warrant. (2006 - 284,000 common shares for

cash proceeds of $241,400)

(5) The long-term debt recorded represents repayable loans from the

Alberta Heritage Foundation. On January 1, 2007, in conjunction with

the adoption of the CICA Handbook section 3855 "Financial

Instruments", this loan was recorded at fair value (see note 3 of the

December 31, 2007 audited financial statements).

(6) We have not declared or paid any dividends since incorporation. <
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... CA (PRWEB) December 23, 2014 Pipette.com ... where their Twitter followers can submit their #HolidayInTheLab pictures ... and their lab mates. , For those struggling to ... mates, the Pipette.com Holiday in the Lab Contest provides ... Pipette.com Twitter followers to send pictures of their ...
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
(Date:12/22/2014)... ROCKVILLE, Md. , Dec. 22, 2014 ... MKT: SYN), a developer of pathogen-specific therapies ... focus on protecting the microbiome, today announced ... a Phase 1a clinical trial of SYN-004, ... the prevention of Clostridium difficile (C. ...
(Date:12/22/2014)... MISSION VIEJO, Calif. , Dec. 22, 2014 /PRNewswire/ ... announce that CoPatient, an online medical bill review and ... newest offering in the FREE WellCard Savings discount health ... a medical bill that was more than they expected ... help members reduce health care costs, WellCard Savings is ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... Semiconductor nanowires tiny wires with a diameter as ... hold promise for devices of the future, both in ... transistors and circuits for next generation of electronics. But ... their composition must be precisely controlled, and researchers must ...
... in the production of sustainable, specialty ingredients and ... Doyle has joined the company as senior vice ... Mike is the former director of nutrition health ... ingredients business initiatives. For more information about ...
... Biovista Inc. today,announced that BVA-101, its drug ... in the MOG-induced Experimental Allergic,Encephalomyelitis (EAE) murine model ... in MS and is aimed at neuroprotection, was ... no toxic effects in this well,established model of ...
Cached Biology Technology:Researchers peer into nanowires to measure dopant properties 2Microbia, Inc. Names Mike Doyle as Senior Vice President and General Manager, Nutrition Ingredients 2Microbia, Inc. Names Mike Doyle as Senior Vice President and General Manager, Nutrition Ingredients 3Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis 2
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. ... the adoption of multimodal biometric systems. Multimodal biometric ... individual for verification and identification purposes. This helps ...
(Date:12/10/2014)... Dec. 9, 2014  Valencell, a leader in performance ... a staggering demand from its licensees for highly accurate, ... is not solely coming from fitness and health sectors, ... "A wearable is only as useful as the ... the ultimate driver in long-term mass consumer adoption of ...
(Date:12/10/2014)...     Jifflenow ...   Jifflenow, a leading provider ... business-to-business (B2B) events, today announced a partnership with ... communication (NFC), Bluetooth low energy (BLE), and cloud-based ... Jifflenow will integrate its meeting scheduling ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... extensive study of pollutants in marine mammals, brains reveals ... of pesticides such as DDTs and PCBs, as well ... Eric Montie, the lead author on the study ... Environmental Pollution , performed the research as a ...
... seems to forget things, will she end up demented? These ... that may signal which 70-year-olds risk developing dementia. This is ... the University of Gothenburg, Sweden. Several of the tests ... do not seem to work any longer. The thesis shows ...
... discovered a new eco-friendly way of dissolving wood using ... products such as bio fuels, textiles, clothes and paper. ... the University,s School of Chemistry and Chemical Engineering worked ... come up with a more cost and energy efficient ...
Cached Biology News:Skip this cocktail party 2Skip this cocktail party 3Early identification of dementia increasingly difficult 2Queen's scientists discover eco-friendly wood dissolution 2
... tubing kit provides high-pressure tubing for ... and other chromatography systems. The kit ... and orange PEEK tubing for the ... chromatography system running at flow rates ...
PTC-100 cycler with gold/silver block with Hot Bonnet heated lid, holds one 96-well V-plate or96x0.2ml tubes...
... The BioGenex Super Sensitive ... based on species-specific secondary antibodies, ... that bind to the bound ... detected by a Streptavidin-Enzyme conjugate. ...
BioGenex IHC Kits for Rodent Tissues are designed for immunohistochemistry on rodent and rabbit tissues that are closely related to the source of the primary antibody. This kit comes with rat seconda...
Biology Products: